A total of @ patients , @-@ years of age , were randomized to receive clindamycin-BP @ % or vehicle in a double-blind , controlled @-week , @-arm study evaluating safety and efficacy using inflammatory and noninflammatory lesion counts , Evaluator Global Severity Scores ( EGSS ) and subject self-assessment ( SSA ) .